This research is to determine which medication, Esmesol (PPI) or Placebo works best at reducing the chance that a patient will get an marginal ulcer after pancreaticoduodenectomy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
360
Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months
SMESOL 40 mg dose administrea daily at bedtime for 6 months after PPPD ,
GangnamSeverance Hospital
Seoul, South Korea
RECRUITINGMarginal ulcer incidence
Number of Participants occurs Endoscopic visualization of presence or absence of marginal ulcers
Time frame: Time Frame: during first 6 months after surgery
QOL
Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia.
Time frame: Time Frame: during first 6 months after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.